A Phase II Study of Fenretinide (NSC # 374551, IND #40294) in Children With Recurrent/Resistant High Risk Neuroblastoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fenretinide (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2013 Biomarkers information updated
- 15 Sep 2011 Actual end date ( Mar 2006) added as reported by ClinicalTrials.gov.
- 21 Sep 2005 New trial record.